Pfizer CEO calls Metsera GLP-1 acquisition “game-changing,” targets 2028 launch

Bullish Gator

Albert Bourla highlights strong primary-care results and the Metsera GLP-1 deal, aiming for a 2028 product launch.

Editorial companion

What stands out

On Mornings with Maria, Pfizer Chairman and CEO Albert Bourla called the Metsera acquisition "game-changing" and emphasized a new glucagon-like peptide-1 (GLP-1) product aimed for a 2028 launch, while pointing to strength in primary care. That matters because Pfizer is signaling a strategic pivot: buying a late-stage growth engine rather than simply trimming costs, and planting a multi-year growth thesis into a company whose current top line is under pressure. For investors, Bourla’s message is less about next quarter earnings and more about how management plans to rebuild Pfizer’s long-term growth runway.